Coloma Jason V 4
4 · Maze Therapeutics, Inc. · Filed May 27, 2026
Research Summary
AI-generated summary of this filing
Maze Therapeutics CEO Jason Coloma Sells 32,564 Shares
What Happened
Jason V. Coloma, CEO of Maze Therapeutics (MAZE), sold a total of 32,564 shares in open-market dispositions across May 22 and May 26, 2026, generating proceeds of about $847,048. Sales reported: 4,504 shares at $26.00 ($117,104), 2,478 shares at $26.00 ($64,428), and 25,582 shares at a weighted average $26.02 ($665,516). At least one of the transactions was effected under a Rule 10b5-1 trading plan adopted Feb 6, 2026.
Key Details
- Transaction dates: May 22, 2026 (two disposals); May 26, 2026 (one disposal). Form filed May 27, 2026.
- Prices: two May 22 disposals reported at $26.00; May 26 disposal WAP $26.02. Footnotes indicate sale prices ranged roughly $26.00–$26.105 per share across multiple executions.
- Total shares sold: 32,564; total proceeds reported: $847,048.
- Holdings after the transactions: not specified in the supplied excerpt (see the full Form 4 for post-transaction holdings).
- Notable footnotes: at least one sale under a Rule 10b5-1 plan (F1); sales executed in multiple trades with weighted-average pricing and listed price ranges (F2, F5); some securities are held by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Coloma and his spouse are co-trustees (F3, F4). The filer offers to provide breakdowns of shares sold at each price upon request.
Context
These were sales (not purchases). Sales executed under a pre-established 10b5-1 plan are commonly scheduled in advance and are considered routine; they do not, by themselves, indicate management’s view of the company’s prospects. For full detail on holdings after the trades or the precise per-trade prices, consult the complete Form 4 filing (Accession 0001676170-26-000007).
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-05-22$26.00/sh−4,504$117,104→ 376,569 total(indirect: By Trust) - Sale
Common Stock
[F1][F4]2026-05-22$26.00/sh−2,478$64,428→ 28,523 total(indirect: By Trust) - Sale
Common Stock
[F1][F5][F3]2026-05-26$26.02/sh−25,582$665,516→ 350,987 total(indirect: By Trust)
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.105 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4.
- [F3]These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.
- [F4]These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.09 per share, inclusive.